EUCRU (Eucrates Biomedical Acquisition) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition ROE % Adjusted to Book Value?

Eucrates Biomedical Acquisition's ROE % for the quarter that ended in Dec. 2022 was 1.03%. Eucrates Biomedical Acquisition's PB Ratio for the quarter that ended in Dec. 2022 was N/A. Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 was N/A.

Eucrates Biomedical Acquisition ROE % Adjusted to Book Value Historical Data

The historical data trend for Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition ROE % Adjusted to Book Value Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value falls into.

Eucrates Biomedical Acquisition ROE % Adjusted to Book Value Calculation

Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	4.49%	/	N/A
	=	N/A

Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	1.03%	/	N/A
	=	N/A

Eucrates Biomedical Acquisition ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020